Tag - Mani Foroohar

Markets

SVB cuts 4D Molecular to MP on elevated risk to Fabry program

SVB Securities downgraded 4D Molecular Therapeutics (NASDAQ:FDMT) to “market perform” from “outperform” and reduced its price target to $12, citing an elevated risk to the lead Fabry disease program, along with an...

August 12, 2022

Markets

SVB Leerink cuts Abeona Therapeutics to MP; PT to $1 from $5

SVB Leerink downgraded Abeona Therapeutics (NASDAQ:ABEO) to “market perform” from “outperform” and slashed its price target to $1 from $5 after stronger-than-expected data from competitor Krystal Biotech (NASDAQ:KRYS). ...

November 30, 2021

Markets

SVB Leerink starts Amryt Pharma at OP: PT $22

SVB Leerink initiated coverage of Amryt Pharma PLC (NASDAQ:AMYT) with an “outperform” rating and price target of $22. Analyst Mani Foroohar, M.D., writes that Amryt’s model of acquiring niche commercial or near...

August 19, 2021

Markets

SVB Leerink cuts AVROBIO PT to $10 from $18

SVB Leerink reduced its price target for AVROBIO (NASDAQ:AVRO) to $10 from $18 but maintained its “market perform” rating after the company announced that it may no longer pursue an accelerated approval pathway for AVR...

May 3, 2021

Markets

SVB Leerink starts Adverum Biotechnologies at OP; PT $17

SVB Leerink launched coverage of Adverum Biotechnologies (NASDAQ:ADVM) with an “outperform” rating and $17 price target. The stock closed at $10.33 on March 13. Adverum’s lead asset, ADVM-022, is in a Phase 1 trial as a...

March 16, 2020

Tag - Mani Foroohar

SVB cuts 4D Molecular to MP on elevated risk to Fabry program

SVB Leerink cuts Abeona Therapeutics to MP; PT to $1 from $5

SVB Leerink starts Amryt Pharma at OP: PT $22

SVB Leerink cuts AVROBIO PT to $10 from $18

SVB Leerink starts Adverum Biotechnologies at OP; PT $17

General

More